See whether Helium helps you make better-informed decisions. Try every Pro Trader feature for 30 days. No credit card required.
Try every Pro Trader feature for 30 days. No credit card required.
Bearish but nuanced: frames Aclaris Therapeutics as facing profitability risk amid ongoing losses while acknowledging growth signals, using data sources and disclaimers to balance analysis and reduce sensationalism.
Stock analysis by Simply Wall Street summarizes Q1 2026 results for Aclaris Therapeutics with US$2.0M revenue, US$0.15 basic EPS loss, trailing US$8.4M revenue and US$0.56 EPS loss, ongoing ~US$20M quarterly losses, a 6.6x P/B, and a 59.6% revenue growth forecast, while profitability remains unlikely soon and citing data sources and non-advisory intent.
Moderately cautious; data-driven but may reflect common financial-media framing.
2026 © Helium Trades
Privacy Policy & Disclosure
* Disclaimer: Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy
of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions,
you should consult a financial expert before engaging in any transaction.
